FindTrial
Sign In

Anti-OX40 Antibody BMS 986178

BIOLOGICAL2 trials

Sponsors

Ronald Levy

Conditions

Advanced Malignant Solid NeoplasmB-Cell Non-Hodgkin LymphomaExtracranial Solid NeoplasmGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaLymphoplasmacytic LymphomaMantle Cell Lymphoma

Phase 1

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
CompletedNCT03410901
Ronald LevyB-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma +5
Start: 2018-04-09End: 2024-10-10Updated: 2024-12-11
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
CompletedNCT03831295
Ronald LevyAdvanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Start: 2019-03-13End: 2021-10-04Updated: 2023-11-22

Related Papers

Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with <i>in Situ</i> Vaccination
Blood2023-11-02
Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma
Blood2022-11-15
Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing
Blood2019-11-135 citations
Abstract 4045: Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing <i>in situ</i> vaccination
Cancer Research2019-07-01
Abstract 4045: Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing<i>in situ</i>vaccination
Clinical Research (Excluding Clinical Trials)2019-07-01